X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (18761) 18761
Book Review (1699) 1699
Publication (525) 525
Newsletter (67) 67
Conference Proceeding (28) 28
Magazine Article (27) 27
Book Chapter (12) 12
Newspaper Article (4) 4
Transcript (3) 3
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17453) 17453
index medicus (17337) 17337
antineoplastic combined chemotherapy protocols - therapeutic use (11650) 11650
female (10929) 10929
male (10863) 10863
vincristine - administration & dosage (9395) 9395
middle aged (7708) 7708
adult (7412) 7412
vincristine - therapeutic use (7240) 7240
cyclophosphamide - administration & dosage (6228) 6228
aged (5686) 5686
doxorubicin - administration & dosage (5660) 5660
oncology (5476) 5476
prednisone - administration & dosage (4325) 4325
cyclophosphamide - therapeutic use (4279) 4279
chemotherapy (3965) 3965
adolescent (3864) 3864
prednisone - therapeutic use (3521) 3521
combined modality therapy (3233) 3233
doxorubicin - therapeutic use (3202) 3202
child (3193) 3193
treatment outcome (3182) 3182
prognosis (3001) 3001
vincristine (2938) 2938
hematology (2899) 2899
antineoplastic combined chemotherapy protocols - administration & dosage (2534) 2534
child, preschool (2434) 2434
antineoplastic combined chemotherapy protocols - adverse effects (2403) 2403
abridged index medicus (2332) 2332
cancer (2203) 2203
methotrexate - administration & dosage (2099) 2099
remission induction (2042) 2042
vincristine - adverse effects (2013) 2013
etoposide - administration & dosage (1909) 1909
neoplasm staging (1769) 1769
antineoplastic agents - therapeutic use (1755) 1755
drug therapy, combination (1754) 1754
follow-up studies (1725) 1725
retrospective studies (1674) 1674
lymphoma, non-hodgkin - drug therapy (1647) 1647
infant (1623) 1623
lymphoma, large b-cell, diffuse - drug therapy (1609) 1609
rituximab (1590) 1590
bleomycin - administration & dosage (1585) 1585
disease-free survival (1506) 1506
survival rate (1503) 1503
methotrexate - therapeutic use (1453) 1453
hodgkin disease - drug therapy (1387) 1387
aged, 80 and over (1373) 1373
therapy (1371) 1371
time factors (1343) 1343
cyclophosphamide (1333) 1333
animals (1317) 1317
survival analysis (1298) 1298
drug administration schedule (1243) 1243
procarbazine - administration & dosage (1239) 1239
cyclophosphamide - adverse effects (1180) 1180
prednisolone - administration & dosage (1151) 1151
cisplatin - administration & dosage (1139) 1139
doxorubicin - adverse effects (1104) 1104
doxorubicin (1103) 1103
lymphomas (1081) 1081
non-hodgkins-lymphoma (1024) 1024
survival (1024) 1024
cytarabine - administration & dosage (1018) 1018
pediatrics (1014) 1014
lung neoplasms - drug therapy (995) 995
care and treatment (983) 983
radiotherapy (962) 962
prednisone - adverse effects (934) 934
clinical trials as topic (895) 895
children (852) 852
young adult (851) 851
prospective studies (848) 848
dexamethasone - administration & dosage (812) 812
dactinomycin - administration & dosage (798) 798
lymphoma (781) 781
lymphoma - drug therapy (781) 781
recurrence (775) 775
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (773) 773
lymphoma, large b-cell, diffuse - pathology (759) 759
procarbazine - therapeutic use (757) 757
leukemia, lymphoid - drug therapy (720) 720
neoplasm metastasis (711) 711
pharmacology & pharmacy (705) 705
risk factors (700) 700
antibodies, monoclonal, murine-derived (697) 697
dacarbazine - administration & dosage (680) 680
medicine & public health (672) 672
cytarabine - therapeutic use (671) 671
tumors (671) 671
mice (670) 670
remission, spontaneous (647) 647
trial (646) 646
bleomycin - therapeutic use (640) 640
multiple myeloma - drug therapy (640) 640
carcinoma, small cell - drug therapy (629) 629
medicine, general & internal (629) 629
mechlorethamine - administration & dosage (628) 628
dactinomycin - therapeutic use (624) 624
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15389) 15389
Japanese (999) 999
German (674) 674
French (446) 446
Chinese (300) 300
Spanish (282) 282
Russian (238) 238
Italian (184) 184
Polish (176) 176
Hungarian (30) 30
Dutch (25) 25
Hebrew (17) 17
Danish (15) 15
Portuguese (14) 14
Czech (12) 12
Serbian (12) 12
Norwegian (7) 7
Romanian (7) 7
Swedish (7) 7
Ukrainian (7) 7
Bulgarian (5) 5
Croatian (5) 5
Finnish (5) 5
Slovak (3) 3
Turkish (3) 3
Korean (2) 2
Lithuanian (2) 2
Bosnian (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 23, pp. 2690 - 2697
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Positron-Emission Tomography | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Treatment Failure | Hodgkin Disease - drug therapy | Adult | Female | Radiotherapy Dosage | Etoposide - adverse effects | Prednisone - adverse effects | Proportional Hazards Models | Etoposide - therapeutic use | Treatment Outcome | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 20, pp. 2260 - 2267
Journal Article
Blood, ISSN 0006-4971, 07/2011, Volume 118, Issue 1, pp. 37 - 43
Journal Article
The Lancet, ISSN 0140-6736, 12/2017, Volume 390, Issue 10114, pp. 2790 - 2802
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2012, Volume 30, Issue 28, pp. 3452 - 3459
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2015, Volume 169, Issue 5, pp. 672 - 682
This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti‐ CC chemokine receptor 4... 
mogamulizumab | study | CCR | randomized phase | adult T‐cell leukaemia‐lymphoma | antibody therapy | Adult T-cell leukaemia-lymphoma | Mogamulizumab | Antibody therapy | CCR4 | Randomized phase II study | randomized phase II study | adult T-cell leukaemia-lymphoma | MONOCLONAL-ANTIBODY KW-0761 | RECEPTOR | LEUKEMIA/LYMPHOMA | HEMATOLOGY | EXPRESSION | ASSOCIATION | TRANSPLANTATION | Doxorubicin - therapeutic use | Nitrosourea Compounds - adverse effects | Prednisolone - adverse effects | Nitrosourea Compounds - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Carboplatin - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Carboplatin - therapeutic use | Vindesine - adverse effects | Vindesine - therapeutic use | Aged, 80 and over | Adult | Female | Prednisolone - therapeutic use | Etoposide - adverse effects | Leukemia-Lymphoma, Adult T-Cell - mortality | Etoposide - therapeutic use | Treatment Outcome | Leukemia-Lymphoma, Adult T-Cell - pathology | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Chemotherapy | Lymphomas | T cells | Leukemia | Cancer | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Journal Article